Disproportionality Analysis and Causal Inference in Drug Safety

被引:0
|
作者
Scosyrev, Emil [1 ]
Behr, Sigrid [2 ]
Jain, Devendra [2 ]
Ponnuru, Arun [3 ]
Michel, Christiane [2 ]
机构
[1] Novartis Pharmaceut, Quantitat Safety & Epidemiol, One Hlth Pl, E Hanover, NJ 07936 USA
[2] Novartis Pharm AG, Basel, Switzerland
[3] Novartis Healthcare Pvt Ltd, Hyderabad, India
关键词
PHARMACOVIGILANCE SIGNAL-DETECTION; SPONTANEOUS REPORTING SYSTEMS; CANCER;
D O I
10.1007/s40290-024-00549-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Disproportionality analysis is a method of safety signal detection based on quantitative analysis of spontaneous reports of adverse events. Disproportionality findings are often presented in medical publications as real-world evidence on drug safety. In this paper, we review theoretical properties of disproportionality analysis in the framework of causal inference theory. We show that measures of disproportionality can approximate the causal rate ratio for a specific drug-event combination when the study drug and the set of comparator drugs satisfy all of the following conditions: (1) there is no uncontrolled confounding for the drug-event association of interest, (2) under-reporting for the event of interest is either absent or has the same relative magnitude for the study drug and for the comparator drugs, and (3) reporting rates for all adverse events combined are the same for the study drug and for the comparator drug set. Because these conditions are typically not even approximately satisfied in practice, the overwhelming majority of disproportionality hits represent statistical noise rather than causal associations. Researchers choosing to report disproportionality findings in publications should explicitly acknowledge all key assumptions and the exploratory nature of this data-mining technique.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Disproportionality Analysis and Causal Inference in Drug SafetyDisproportionality Analysis and Causal InferenceE. Scosyrev et al.
    Emil Scosyrev
    Sigrid Behr
    Devendra Jain
    Arun Ponnuru
    Christiane Michel
    Pharmaceutical Medicine, 2025, 39 (2) : 97 - 107
  • [2] On Causal Inference and the Limits of Disproportionality as a Construct: The Case of Foster Care Placement
    Wulczyn, Fred
    SOCIAL SERVICE REVIEW, 2023, 97 (02) : 362 - 397
  • [3] Drug-induced membranous nephropathy: Disproportionality analysis of the WHO safety database
    Gerard, A. O.
    Merino, D.
    Cremoni, M.
    Destere, A.
    Teisseyre, M.
    Esnault, V. L. M.
    Sicard, A.
    Seitz-Polski, B.
    Drici, M. D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 62 - 63
  • [4] Causal inference in drug discovery and development
    Michoel, Tom
    Zhang, Jitao David
    DRUG DISCOVERY TODAY, 2023, 28 (10)
  • [5] Robust causal inference of drug-drug interactions
    Shu, Di
    Han, Peisong
    Hennessy, Sean
    Miano, Todd A.
    STATISTICS IN MEDICINE, 2023, 42 (07) : 970 - 992
  • [6] Can disproportionality analysis play a role in monitoring drug-eluting stent safety?
    Duggirala, H.
    Yang, X.
    Van Manen, R.
    CIRCULATION, 2008, 118 (12) : E439 - E439
  • [7] Drug-induced minimal change disease: Disproportionality analysis of the WHO safety database
    Gerard, A. O.
    Merino, D.
    Cremoni, M.
    Destere, A.
    Teisseyre, M.
    Esnault, V. L. M.
    Sicard, A.
    Seitz-Polski, B.
    Drici, M. D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 42 - 42
  • [8] Causal Inference With Mediation Analysis
    Chen, Jianping
    CRITICAL CARE MEDICINE, 2020, 48 (01) : E77 - E78
  • [9] A RATIONAL ANALYSIS OF CAUSAL INFERENCE
    ANDERSON, JR
    BULLETIN OF THE PSYCHONOMIC SOCIETY, 1989, 27 (06) : 517 - 517
  • [10] Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS)
    Charlotte L. Stokes
    Jan Schjøtt
    European Journal of Clinical Pharmacology, 2019, 75 : 1469 - 1470